ACTUATE THERAPEUTICS INC (ACTU) Stock Price, Forecast & Analysis
NASDAQ:ACTU • US0050831009
ACTU Key Statistics, Chart & Performance
The current stock price of ACTU is 4.26 USD. In the past month the price decreased by -25.13%. In the past year, price decreased by -44.6%.
ACTU Technical Analysis
ACTU Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ACTU. Both the profitability and financial health of ACTU have multiple concerns.
ACTU Financial Highlights
Over the last trailing twelve months ACTU reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 49.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.16% | ||
| ROE | -220.55% | ||
| Debt/Equity | 0.04 |
ACTU Forecast & Estimates
10 analysts have analysed ACTU and the average price target is 25.5 USD. This implies a price increase of 498.59% is expected in the next year compared to the current price of 4.26.
ACTU Ownership
ACTU Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.65 | 411.552B | ||
| AMGN | AMGEN INC | 16.82 | 201.047B | ||
| GILD | GILEAD SCIENCES INC | 17.18 | 192.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.23 | 121.106B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.08 | 83.892B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.941B | ||
| INSM | INSMED INC | N/A | 32.101B | ||
| NTRA | NATERA INC | N/A | 29.393B | ||
| BIIB | BIOGEN INC | 12.82 | 28.709B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.17 | 20.773B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACTU
Company Profile
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. The company is headquartered in Fort Worth, Texas and currently employs 10 full-time employees. The company went IPO on 2024-08-13. The firm is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The firm is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Company Info
ACTUATE THERAPEUTICS INC
1751 River Run, Suite 400
Fort Worth TEXAS US
Employees: 10
Phone: 18479864190
ACTUATE THERAPEUTICS INC / ACTU FAQ
What does ACTU do?
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. The company is headquartered in Fort Worth, Texas and currently employs 10 full-time employees. The company went IPO on 2024-08-13. The firm is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The firm is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
What is the stock price of ACTUATE THERAPEUTICS INC today?
The current stock price of ACTU is 4.26 USD.
Does ACTU stock pay dividends?
ACTU does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACTU stock?
ACTU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about ACTUATE THERAPEUTICS INC (ACTU) stock?
10 analysts have analysed ACTU and the average price target is 25.5 USD. This implies a price increase of 498.59% is expected in the next year compared to the current price of 4.26.
What sector and industry does ACTUATE THERAPEUTICS INC belong to?
ACTUATE THERAPEUTICS INC (ACTU) operates in the Health Care sector and the Biotechnology industry.